Somatostatinoma Completed Phase 2 Trials for Gefitinib (DB00317)

Also known as: Somatostatinomas

IndicationStatusPhase
DBCOND0000820 (Somatostatinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00075439Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine TumorsTreatment